摘要
Hepatobiliary malignancies are highly heterogeneous with poor prognosis and drug response [1]. It is difficult to diagnose at an early stage. Hence, precise molecular targets are urgently needed to improve the diagnose efficacy and individual treatment response. However, reliable biomarkers that can predict the individual treatment response are still lacking. With the broad application of high-throughput sequencing technology and bioinformatics analysis in scientific research, increasing numbers of diagnosing molecular targets will be found and tested. Such bioinformatics will provide a more rational way to diagnose, prevent, and treat hepatobiliary cancers [2].
